NCT02067676View on ClinicalTrials.gov

Safety Study of a Capsule-Conjugate Vaccine to Prevent Campylobacter-Caused Diarrhea

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

April 21, 2014

Primary Completion Date

September 24, 2014

Study Completion Date

January 22, 2016

Conditions
Campylobacter Infection
Interventions
BIOLOGICAL

Capsule-Conjugate Campylobacter Vaccine (CJCV1)

The capsule of Campylobacter jejuni strain 81-176 (CPS81-176) conjugated to the mutated diphtheria toxin cross-reacting material 197 (CRM197) (lyophilized CPS-CRM197 conjugate) (CJCV1)

DRUG

Alhydrogel®, aluminum hydroxide adjuvant (alum)

Trial Locations (1)

20910

Walter Reed Army Institute of Research, Silver Spring

All Listed Sponsors
collaborator

Walter Reed Army Institute of Research (WRAIR)

FED

lead

U.S. Army Medical Research and Development Command

FED

NCT02067676 - Safety Study of a Capsule-Conjugate Vaccine to Prevent Campylobacter-Caused Diarrhea | Biotech Hunter | Biotech Hunter